Narrative review of data supporting alternate first-line therapies over metformin in type 2 diabetes

ConclusionGLP-1 RA and SGLT-2i can be considered as first line monotherapies for select patients with high cardiovascular risks, renal disease, or weight loss requirements. However, pharmacoeconomic considerations along with lesser long-term safety outcomes should limit these agents ’ use in certain patients as the management of diabetes continues to transition towards shared-decision making.
Source: Journal of Diabetes and Metabolic Disorders - Category: Endocrinology Source Type: research